Guardant Health, Inc. Stock

Equities

GH

US40131M1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-05 pm EDT 5-day change 1st Jan Change
31.19 USD +11.43% Intraday chart for Guardant Health, Inc. +19.55% +15.30%
Sales 2024 * 681M Sales 2025 * 812M Capitalization 3.43B
Net income 2024 * -385M Net income 2025 * -342M EV / Sales 2024 * 5.4 x
Net Debt 2024 * 253M Net Debt 2025 * 481M EV / Sales 2025 * 4.81 x
P/E ratio 2024 *
-8.78 x
P/E ratio 2025 *
-9.45 x
Employees 1,774
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.47%
More Fundamentals * Assessed data
Dynamic Chart
1 day+11.43%
1 week+19.55%
Current month+15.09%
1 month+63.30%
3 months+66.17%
6 months+18.10%
Current year+15.30%
More quotes
1 week
26.06
Extreme 26.06
32.30
1 month
18.01
Extreme 18.01
32.30
Current year
15.81
Extreme 15.81
32.30
1 year
15.81
Extreme 15.81
41.06
3 years
15.81
Extreme 15.81
133.82
5 years
15.81
Extreme 15.81
181.07
10 years
15.81
Extreme 15.81
181.07
More quotes
Managers TitleAgeSince
Founder 48 11-12-31
Founder 44 11-12-31
Chief Executive Officer 45 12-12-31
Members of the board TitleAgeSince
Director/Board Member 62 16-11-30
Director/Board Member 65 21-10-14
Director/Board Member 49 20-05-31
More insiders
Date Price Change Volume
24-06-05 31.19 +11.43% 6,650,900
24-06-04 27.99 +2.12% 2,424,600
24-06-03 27.41 +1.14% 2,420,575
24-05-31 27.1 -1.35% 3,615,994
24-05-30 27.47 +5.29% 2,077,828

Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT

More quotes
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
27.99 USD
Average target price
37.53 USD
Spread / Average Target
+34.07%
Consensus